We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Polarean Imaging Plc | POLX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.90 | 08:00:04 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.90 | 3.90 | 3.90 | 3.90 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 17/4/2024 09:11 by wetdream Aren’t they using Phillips sales force?Also, surely the research hospitals’ contracts specify a fixed time period for deciding to go ahead on a commercial basis or return the technology to POLX? |
Posted at 06/4/2024 10:57 by gregb Cheers DYM Turbo.I can't see the POLX application on the MHRA website. Nor do I see why we need an academic institution to support when the application is a paper submission exercise. |
Posted at 06/4/2024 09:16 by gregb Since Jeremy Hunt's 2023 budget, the UK MHRA offers "near automatic sign-off" for medicines and technologies approved by other trusted regulators, such as the United States, Europe and Japan. I have no idea why POLX hasn't applied for the above for the very small amount of money it would cost. |
Posted at 06/4/2024 07:34 by john henry i disagree Goldbutler with the limited resources POLX have at present i think its correct to focus on the US where they have clinical clearance. |
Posted at 05/4/2024 19:03 by john henry Goldbutler i guess you didn't note that the study is pediatric.POLX approval doesnt cover patience age 12 and under. |
Posted at 04/4/2024 14:23 by john henry You beat me to it Amaretto, POLX DEST AGL and many more will delist 2024-25.IMHO there wont be any small Biotech Tech stocks available for UK investment over the next few years. |
Posted at 14/3/2024 09:47 by dym turbo Cherster, did you read the RNS from Amati this morning?When you see Strategic Review in the title of an RNS on AIM you know there is a mess at play! I can 100% guarantee you that Amait would not be selling their stake to Nukem at 5p when the 2 main Strategic Investors have confirmed they will back to company long term! We all know Amati wanted the POLX sold last year and they also blocked the 40p fundraise in April! Mmmm, I wonder why?? I’m sorry to see Amati go and feel they have been an excellent investor to POLX over the years but that RNS this morning was peppering over the cracks of a horrendous few years for the them – end of story! |
Posted at 14/3/2024 09:00 by chester9 Amati and Miton have seriously underperformed with the outflows from uk funds to funds with more global returns it may take longer yet for small companies to attract investment not least when 250 still cheap and being raided. It's a waiting game for the money to flow lower. Amati no longer waiting and much better bets than Polx. Polx running out of fans and cash, like many others. |
Posted at 12/2/2024 10:23 by w t tutte This has just populated in the last few day ..... One would think Duke will need the FDA approved system for this ..... collaboration with the American Heart Association and validation work for POLX, that POLX does not have to pay for and its in a new indication. |
Posted at 07/9/2023 11:22 by fft A number of Polarean shareholders have good reasons for Polarean not to fail. But, and this is the big question, what is their price for taking POLX over ? For example, Nukem. They sell isotopes used by the machines. They have invested a certain amount in POLX and don't want to lose that, but will the amount they make from further isotope sales make rescuing POLX worthwhile or is just better to step aside and let others buy it / write off the investment ? They also don't appear to be that wealthy a company from what I can see so would need to borrow to fully take it over. What is POLX worth to other companies ? Probably depends on the time frame.It would appear to be worth something to everyone, so my hope/thoughts are that the players in the industry who have agreements/sharehold |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
